Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory
All Press Releases for January 27, 2010 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Avail Clinical Research Announces Irritable Bowel Syndrome Research Studies in DeLand, FL
Irritable Bowel Syndrome research studies for those already diagnosed with IBS being conducted in DeLand, FL. 
x-small text small text medium text large text


    DELAND, FL, January 27, 2010 /24-7PressRelease/ -- Avail Clinical Research, a privately owned research facility, founded in 1998 in DeLand, FL, announces the launch of several research studies to test investigational treatment options for those already diagnosed with Irritable Bowel Syndrome (IBS). "We are very pleased to begin the systemic evaluation of our research studies to help find a viable investigational treatment solution to those suffering from Irritable Bowel Syndrome," said Bruce G. Rankin, DO, CPI., the Vice Chief of Medicine at Florida Hospital DeLand. "We believe that these research studies will build significantly on the data generated by other studies conducted on investigational treatment options for Irritable Bowel Syndrome." Dr. Rankin has been conducting research with Avail Clinical Research since 1999 and is currently the Medical Director.

The research studies will enroll those already diagnosed with IBS, which includes symptoms like abdominal pain, bloating, diarrhea and constipation. In order to participate in the studies volunteers must be diagnosed with IBS. Avail Clinical Research will not take volunteers who:
have any evidence or treatment of malignancy within the previous 5 years,
have a history of alcohol or substance abuse within the previous 5 years,
have used an investigatory drug or participated in an investigatory study within 30 days of the screening,
are pregnant, or
are breast-feeding.

Irritable bowel syndrome (IBS) refers to a complex disorder of the lower intestinal tract. It is mainly characterized by a pattern of symptoms that is often worsened by emotional stress. Avail Clinical Research will provide participants with study related care, including physical examinations, laboratory services and study medications. Participants will also be compensated for time and travel. For more information regarding participation in our research studies, contact Avail Clinical Research at (386) 310-1334, or at http://www.AvailClinical.com.

About Avail Clinical Research

Avail Clinical Research is currently conducting a wide array of clinical studies targeted towards certain conditions. You may be eligible to participate in one of our clinical trials and contribute to the development and approval of a new drug or treatment. As a participant, there is no cost to you at any point during the study and health insurance is not required. Browse our clinical trials being conducted now to find the study best suited for you.


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #


Read more Press Releases from Sach Chitnis:
Other Press Release Headlines:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Sach Chitnis
Avail Clinical Research

Senior Vice President
860 Peachwood Dr.
DeLand, FL
United States 32720
Voice: (386) 310-1334
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.